Temozolomide

Search with Google Search with Bing

Information
Drug Name
Temozolomide
Description
Entry(CIViC)
14
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
malignant astrocytoma ATRX UNDEREXPRESSION
( ENST00000373344.11 ) ATRX UNDEREXPRESSION
( ENST00000373344.11 ) 		B Predictive Supports N/A 3 23904111 Detail
melanoma NRAS p.Gln61Leu (p.Q61L)
( ENST00000369535.5 ) NRAS p.Gln61Leu (p.Q61L)
( ENST00000369535.5 ) 		C Predictive Supports Sensitivity/Response Somatic 2 21576590 Detail
melanoma NRAS p.Gln61Arg (p.Q61R)
( ENST00000369535.5 ) NRAS p.Gln61Arg (p.Q61R)
( ENST00000369535.5 ) 		C Predictive Supports Sensitivity/Response Somatic 2 21576590 Detail
brain glioma IDH1 p.Arg132Cys (p.R132C)
( ENST00000345146.7, ENST00000446179.5, ENST00000415913.5 ) IDH1 p.Arg132Cys (p.R132C)
( ENST00000345146.7, ENST00000415913.5, ENST00000446179.5 ) 		B Predictive Supports Sensitivity/Response Somatic 2 20975057 Detail
glioblastoma MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		B Predictive Supports Sensitivity/Response N/A 3 17442989 Detail
high grade glioma MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		B Predictive Supports Sensitivity/Response N/A 3 21365007 Detail
oligodendroglioma MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		B Predictive Supports Sensitivity/Response N/A 2 16541434 Detail
glioblastoma MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		B Predictive Supports Sensitivity/Response N/A 3 21331613 Detail
neuroendocrine tumor MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		B Predictive Supports Sensitivity/Response N/A 2 19118063 Detail
glioblastoma MGMT PROMOTER METHYLATION MGMT PROMOTER METHYLATION A Predictive Supports Sensitivity/Response Somatic 5 15758010 Detail
glioblastoma ATM MUTATION ATM MUTATION D Predictive Supports Sensitivity/Response Somatic 3 23960094 Detail
melanoma ATM MUTATION ATM MUTATION D Predictive Supports Sensitivity/Response Somatic 3 23960094 Detail
glioblastoma BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY C Predictive Supports Sensitivity/Response Unknown 3 31619547 Detail
glioblastoma MGMT c.-28C>T
( ENST00000651593.1, ENST00000306010.8 ) MGMT c.-28C>T
( ENST00000306010.8, ENST00000651593.1 ) 		B Predictive Supports Sensitivity/Response Common Germline 3 25910840 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A retrospective tumor sample study found that the ... ATRX ATRX UNDEREXPRESSION
( ENST00000373344.11 ) ATRX UNDEREXPRESSION
( ENST00000373344.11 ) 		N/A true CIViC Evidence detail
In a melanoma patient with NRAS Q61L mutation, tre... NRAS NRAS p.Gln61Leu (p.Q61L)
( ENST00000369535.5 ) NRAS p.Gln61Leu (p.Q61L)
( ENST00000369535.5 ) 		Sensitivity true CIViC Evidence detail
In a melanoma patient with Q61R mutation, treatmen... NRAS NRAS p.Gln61Arg (p.Q61R)
( ENST00000369535.5 ) NRAS p.Gln61Arg (p.Q61R)
( ENST00000369535.5 ) 		Sensitivity true CIViC Evidence detail
In a study of 189 low-grade gliomas, IDH (IDH1 or ... IDH1 IDH1 p.Arg132Cys (p.R132C)
( ENST00000345146.7, ENST00000446179.5, ENST00000415913.5 ) IDH1 p.Arg132Cys (p.R132C)
( ENST00000345146.7, ENST00000415913.5, ENST00000446179.5 ) 		Sensitivity true CIViC Evidence detail
In this study, patients with low MGMT expression, ... MGMT MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		Sensitivity true CIViC Evidence detail
This study showed that low MGMT mRNA expression wa... MGMT MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		Sensitivity true CIViC Evidence detail
In this study, loss of chromosome 1p and low MGMT ... MGMT MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		Sensitivity true CIViC Evidence detail
In 41 glioblastomas treated with temozolomide (TMZ... MGMT MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		Sensitivity true CIViC Evidence detail
Among those patients who received temozolomide-bas... MGMT MGMT UNDEREXPRESSION
( ENST00000306010.8 ) MGMT UNDEREXPRESSION
( ENST00000306010.8 ) 		Sensitivity true CIViC Evidence detail
In a randomized clinical trial, patients with MGMT... MGMT MGMT PROMOTER METHYLATION MGMT PROMOTER METHYLATION Sensitivity true CIViC Evidence detail
Glioblastoma cell lines were shown to have increas... ATM ATM MUTATION ATM MUTATION Sensitivity true CIViC Evidence detail
Melanoma cell lines were shown to have increased s... ATM ATM MUTATION ATM MUTATION Sensitivity true CIViC Evidence detail
In a case report, a 3‐year‐old girl with glioblast... BRCA2 BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY Sensitivity true CIViC Evidence detail
The T allele of the rs16906252 SNP was associated ... MGMT MGMT c.-28C>T
( ENST00000651593.1, ENST00000306010.8 ) MGMT c.-28C>T
( ENST00000306010.8, ENST00000651593.1 ) 		Sensitivity true CIViC Evidence detail
Inhibition of MGMT with O6-benzylguanine resulted ... MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
Melanoma cells with wild type p53 had much reduced... TP53 TP53 WILD_TYPE Sensitivity true MMMP detail
Measurements of pretreatment levels of MGMT in mel... MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
PARP1, POLB, APEX1, LIG1 and MPG showed no correla... PARP1 PARP1 EXPRESSION Resitance or Non-Reponse true MMMP detail
PARP1, POLB, APEX1, LIG1 and MPG showed no correla... POLB POLB EXPRESSION Resitance or Non-Reponse true MMMP detail
PARP1, POLB, APEX1, LIG1 and MPG showed no correla... APEX1 APEX1 EXPRESSION Resitance or Non-Reponse true MMMP detail
PARP1, POLB, APEX1, LIG1 and MPG showed no correla... LIG1 LIG1 EXPRESSION Resitance or Non-Reponse true MMMP detail
PARP1, POLB, APEX1, LIG1 and MPG showed no correla... MPG MPG EXPRESSION Resitance or Non-Reponse true MMMP detail
The O(6)-methylguanine-DNA methyltransferase (MGMT... MGMT MGMT OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
Melanoma lines expressing p53 wild-type were more ... TP53 TP53 WILD_TYPE Resitance or Non-Reponse true MMMP detail
O(6)-methylguanine DNA-methyltransferase (MGMT) ov... MGMT MGMT OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
Blocking the expression of APP by RNA interference... APP APP UNDEREXPRESSION Sensitivity true MMMP detail
mRNA expression of MGMT, MLH1 and MSH2 in the peri... MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
mRNA expression of MGMT, MLH1 and MSH2 in the peri... MLH1 MLH1 EXPRESSION Resitance or Non-Reponse true MMMP detail
mRNA expression of MGMT, MLH1 and MSH2 in the peri... PMS1 PMS1 EXPRESSION Resitance or Non-Reponse true MMMP detail
The genetic variant rs2303428 (MSH2) might serve a... MSH2 MSH2 rs2303428 MSH2 c.2006-6T>C
( ENST00000543555.6, ENST00000233146.7, ENST00000406134.5, ENST00000645506.1, ENST00000713854.1, ENST00000713919.1 ) MSH2 rs2303428 		Sensitivity true MMMP detail
In this phase II study of extended-dose TMZ in pat... MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
In this phase II study of extended-dose TMZ in pat... MGMT MGMT METHYLATION Resitance or Non-Reponse true MMMP detail
These data show that Rev3L contributes to temozolo... REV3L REV3L UNDEREXPRESSION Sensitivity true MMMP detail
MGMT causes resistance to TMZ MGMT MGMT UNKNOWN Resitance or Non-Reponse true MMMP detail
The authors screened 2,000 compounds from the Spec... DHFR DHFR UNDEREXPRESSION Sensitivity true MMMP detail
Dasatinib in combination with the chemotherapy dru... SRC SRC UNDEREXPRESSION Sensitivity true MMMP detail
MGMT causes resistance to TMZ MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
Inhibition of MGMT with O6-benzylguanine resulted ... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
It is unclear why inhibition of p53 with PFT-alpha... TP53 TP53 UNDEREXPRESSION Sensitivity true MMMP detail
4BTG was less toxic (but equally effective) than O... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
MGMT inactivation by O(6)-benzylguanine sensitized... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
Compounds 24 and 44, featuring an oxadiazole and a... PARP1 PARP1 UNDEREXPRESSION Sensitivity true MMMP detail
Isolated limb infusion model (locoregional therapy... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
BMS-345541 is an IKKB inhibitor and thus a NFkB in... IKBKB IKBKB UNDEREXPRESSION Sensitivity true MMMP detail
Interleukin-24 overcomes temozolomide resistance a... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
Dasatinib does not act synergically with temozolom... SRC SRC UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
The receptor protein tyrosine kinase TYRO3 is an u... TYRO3 TYRO3 UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
Phase III RCT. Setting: advanced disease. No thera... IFNAR1 IFNAR1 OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
In this phase I study of extended dosing with lome... MGMT MGMT UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
CD4+ T cells activated with anti-CD3 and anti-CD28... CD28 CD28 OVEREXPRESSION Sensitivity true MMMP detail
RCT of the combination of lomeguatrib and temozolo... MGMT MGMT UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
Overall response rate: 18% (not greater than expec... IFNAR1 IFNAR1 OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
IL-2: high dose. The overall response rate and the... IL2RA IL2RA OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
Stable depletion of poly (ADP-ribose) polymerase-1... PARP1 PARP1 UNDEREXPRESSION Sensitivity true MMMP detail
MGMT showed a significant correlation with temozol... MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
MGMT showed a significant correlation with temozol... MGMT MGMT OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
No correlation was observed between MGMT promoter ... MGMT MGMT METHYLATION Resitance or Non-Reponse true MMMP detail
These results support development of IGF1R targeti... IGF1R IGF1R UNDEREXPRESSION Sensitivity true MMMP detail
bFGF overexpression can result in resistance again... FGF2 FGF2 EXPRESSION Resitance or Non-Reponse true MMMP detail
Original: underexpression associated with increase... MGMT MGMT EXPRESSION toxicity decrease true MMMP detail
The 93 patients were treated with DTIC or TMZ. Leu... MGMT MGMT EXPRESSION toxicity decrease true MMMP detail
The genetic variant rs2303428 (MSH2) might serve a... MSH2 MSH2 rs2303428 MSH2 c.2006-6T>C
( ENST00000543555.6, ENST00000233146.7, ENST00000406134.5, ENST00000645506.1, ENST00000713854.1, ENST00000713919.1 ) MSH2 rs2303428 		toxicity increased true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT04901702 Active, not recruiting Phase 1/Phase 2 Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma June 9, 2021 December 31, 2025
NCT01849146 Active, not recruiting Phase 1 Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma August 19, 2013 March 4, 2025
NCT04216329 Active, not recruiting Phase 1 Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma July 7, 2020 July 30, 2026
NCT04200443 Active, not recruiting Phase 2 Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma January 14, 2020 June 1, 2024
NCT01858168 Active, not recruiting Phase 1 Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma July 2013 December 2024
NCT03323034 Active, not recruiting Phase 1 Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma January 11, 2018 September 22, 2024
NCT00268385 Active, not recruiting Phase 1 Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas December 16, 2005 April 24, 2025
NCT03709680 Active, not recruiting Phase 1/Phase 2 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors May 24, 2019 February 25, 2025
NCT03688178 Active, not recruiting Phase 2 DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab August 26, 2020 March 2025
NCT04525014 Active, not recruiting Phase 1 RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors January 26, 2023 December 31, 2024
NCT01752491 Active, not recruiting Phase 1 A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme April 1, 2013 December 31, 2024
NCT02179086 Active, not recruiting Phase 2 Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma October 27, 2014 May 2026
NCT02781792 Active, not recruiting Phase 2 Temozolomide Chronotherapy for High Grade Glioma August 11, 2016 July 14, 2024
NCT04400188 Active, not recruiting Phase 1/Phase 2 A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer June 11, 2020 June 2023
NCT02308527 Active, not recruiting Phase 2 Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children July 2013 February 2026
NCT00626990 Active, not recruiting Phase 3 Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH) December 2007 December 2029
NCT03587038 Active, not recruiting Phase 1 OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma September 3, 2018 November 2026
NCT03581292 Active, not recruiting Phase 2 Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations November 6, 2018 September 22, 2024
NCT03576612 Active, not recruiting Phase 1 GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas February 27, 2018 October 31, 2023
NCT04195139 Active, not recruiting Phase 2 Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM February 22, 2018 December 31, 2025
NCT01430351 Active, not recruiting Phase 1 Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy September 14, 2011 September 30, 2025
NCT03556384 Active, not recruiting Phase 2 Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) September 12, 2018 June 2025
NCT04397679 Active, not recruiting Phase 1 Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma August 12, 2021 April 27, 2026
NCT00978458 Active, not recruiting Phase 3 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma November 17, 2009 December 31, 2026
NCT02975882 Active, not recruiting Phase 1 Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors August 15, 2017 September 22, 2024
NCT03137888 Active, not recruiting Phase 2 Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma September 20, 2017 January 4, 2025
NCT04900792 Active, not recruiting Phase 1 A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma February 28, 2023 December 31, 2025
NCT03528642 Active, not recruiting Phase 1 Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma May 1, 2019 December 5, 2024
NCT01991977 Active, not recruiting Phase 2 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy December 2013 December 14, 2024
NCT02715609 Active, not recruiting Phase 1/Phase 2 Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma June 15, 2016 September 2, 2024
NCT01009788 Active, not recruiting Phase 2 ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer November 2009 June 2024
NCT02152982 Active, not recruiting Phase 2/Phase 3 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme December 15, 2014 December 15, 2024
NCT03189706 Active, not recruiting Early Phase 1 Study of Chemoimmunotherapy for High-Risk Neuroblastoma June 12, 2017 June 2024
NCT01946529 Active, not recruiting Phase 2 Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors December 27, 2013 July 2026
NCT04396860 Active, not recruiting Phase 2/Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma September 1, 2020 March 11, 2025
NCT04047706 Active, not recruiting Phase 1 Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma August 13, 2019 June 1, 2025
NCT02344355 Active, not recruiting Phase 2 A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme March 13, 2017 December 2027
NCT05190315 Active, not recruiting Phase 1 Chlorpromazine and Standard of Care in Glioblastoma January 28, 2022 July 2024
NCT04019327 Active, not recruiting Phase 1/Phase 2 A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer July 11, 2019 July 2027
NCT03514069 Active, not recruiting Phase 1 Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma June 5, 2018 December 31, 2024
NCT01824875 Active, not recruiting Phase 2 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors August 8, 2013 December 2024
NCT03880019 Active, not recruiting Phase 2 A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma August 19, 2019 September 21, 2024
NCT03491683 Active, not recruiting Phase 1/Phase 2 INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) May 31, 2018 December 31, 2024
NCT03180502 Active, not recruiting Phase 2 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma August 2, 2017 January 2030
NCT03174197 Active, not recruiting Phase 1/Phase 2 Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma June 30, 2017 June 30, 2025
NCT02655601 Active, not recruiting Phase 2 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 September 25, 2018 December 2024
NCT03794349 Active, not recruiting Phase 2 Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma July 8, 2019 March 31, 2025
NCT03782415 Active, not recruiting Phase 1/Phase 2 Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma December 29, 2018 June 30, 2024
NCT02595424 Active, not recruiting Phase 2 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery April 6, 2016 January 1, 2029
NCT02455557 Active, not recruiting Phase 2 SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma May 4, 2015 December 30, 2024
NCT04385277 Active, not recruiting Phase 2 Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) December 31, 2020 September 26, 2024
NCT06105619 Active, not recruiting Phase 2/Phase 3 A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). October 8, 2018 December 31, 2024
NCT01139970 Active, not recruiting Phase 1 Veliparib and Temozolomide in Treating Patients With Acute Leukemia May 21, 2010 February 22, 2025
NCT01864109 Active, not recruiting Phase 2 Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma May 2013 May 2027
NCT00539591 Active, not recruiting Phase 2 Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma May 9, 2008 May 2026
NCT02761070 Active, not recruiting Phase 3 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III July 11, 2016 November 10, 2025
NCT04324840 Active, not recruiting Phase 1 A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma July 10, 2020 May 15, 2026
NCT04280848 Active, not recruiting Phase 2 Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma May 26, 2020 December 2024
NCT04238819 Active, not recruiting Phase 1/Phase 2 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma November 9, 2020 October 2028
NCT04743661 Active, not recruiting Phase 2 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma April 4, 2022 October 30, 2030
NCT03351296 Active, not recruiting Phase 2 Two Chemotherapy Regimens Plus or Minus Bevacizumab June 26, 2018 December 2028
NCT00555399 Active, not recruiting Phase 1/Phase 2 Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) November 28, 2007 November 20, 2024
NCT05663125 Active, not recruiting Phase 1/Phase 2 LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas December 1, 2022 December 30, 2024
NCT03728361 Active, not recruiting Phase 2 Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer December 31, 2018 December 31, 2024
NCT00114140 Completed Phase 2 Temozolomide and Radiation Therapy in Treating Patients With Gliomas January 2005 May 20, 2022
NCT00128700 Completed Phase 1/Phase 2 Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme June 2005
NCT00137774 Completed Phase 2 Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors November 2004 December 2012
NCT00138216 Completed Phase 1 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors October 2005 January 2011
NCT00165360 Completed Phase 2 Prolonged Daily Temozolomide for Low-Grade Glioma September 2001 September 2009
NCT00182819 Completed Phase 3 Radiation Therapy or Temozolomide in Treating Patients With Gliomas July 2005 May 2014
NCT00194766 Completed Phase 2 Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer July 2000 December 2006
NCT00200161 Completed Phase 2 Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma August 9, 2005 May 4, 2017
NCT00238251 Completed Phase 2 Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases May 2005 November 2010
NCT00003062 Completed Phase 2 Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer July 1997
NCT00253487 Completed N/A Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas August 2005 August 2012
NCT00257205 Completed Phase 3 CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy March 2006 August 2010
NCT00262730 Completed Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM January 2006 April 2010
NCT00274833 Completed Phase 2 Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme October 2005 September 2012
NCT00275002 Completed Phase 2 O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors February 2006 December 2010
NCT00276679 Completed Phase 2 Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma April 2003 November 2006
NCT00301067 Completed Phase 1/Phase 2 Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma January 30, 2005 July 9, 2012
NCT00302159 Completed Phase 2 Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors March 2006 November 2014
NCT00303940 Completed Phase 1 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors December 2005 February 2010
NCT00305864 Completed Phase 1/Phase 2 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma February 9, 2006 March 15, 2011
NCT00311584 Completed Phase 2 Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma April 2006 December 2013
NCT00313729 Completed Phase 2 Temozolomide in Treating Patients With Low-Grade Glioma May 1999 June 12, 2017
NCT00316849 Completed Phase 1 Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme May 2006
NCT00323115 Completed Phase 2 Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme May 2006 July 2013
NCT00335075 Completed Phase 3 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) March 2, 2005 February 23, 2006
NCT00338130 Completed Phase 2 Randomised Study to Compare the Efficacy of AZD6244 vs TMZ July 2006 July 2013
NCT00354068 Completed Phase 1 Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma July 2004 November 2008
NCT00362570 Completed Phase 2 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma May 2005 March 2011
NCT00362817 Completed Phase 1/Phase 2 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases October 2004 February 2008
NCT00385853 Completed Phase 1 PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs September 2006 September 2011
NCT00387400 Completed Phase 1 Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme March 20, 2007 January 6, 2012
NCT00390403 Completed Phase 1 Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme February 2007
NCT00392171 Completed Phase 2 The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) June 9, 2006 September 15, 2009
NCT00400816 Completed Phase 2 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma August 2005 January 6, 2016
NCT00401180 Completed Phase 1 Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer June 2002 July 2008
NCT00402116 Completed Phase 1/Phase 2 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients September 2006 December 2009
NCT00404495 Completed Phase 2 Combination of Irinotecan and Temozolomide in Children With Brain Tumors. April 2007 December 2011
NCT00416819 Completed N/A Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma September 2003 February 2012
NCT00424554 Completed Phase 2 Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) September 26, 2006 February 16, 2011
NCT00433381 Completed Phase 2 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma March 1, 2007 February 16, 2011
NCT00441142 Completed Phase 1/Phase 2 Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors May 25, 2007 October 10, 2017
NCT00458601 Completed Phase 2 Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme August 2007 May 2016
NCT04122911 Completed Phase 2 Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas January 29, 2017 December 16, 2019
NCT00481455 Completed Phase 2 Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) April 2007 October 2008
NCT00482677 Completed Phase 3 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme November 14, 2007 August 10, 2016
NCT00486603 Completed Phase 1/Phase 2 Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme October 29, 2007 January 2014
NCT00492141 Completed Phase 1/Phase 2 Aerosol L9-NC and Temozolomide in Ewing's Sarcoma June 2006 September 2009
NCT00498927 Completed Phase 2 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma June 2007 December 2013
NCT00504660 Completed Phase 2 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients September 2003 August 2010
NCT03914742 Completed Phase 1/Phase 2 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations January 3, 2020 October 31, 2023
NCT03832621 Completed Phase 2 NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer March 25, 2019 September 30, 2021
NCT00521001 Completed Phase 2 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery January 2008 December 2010
NCT03778294 Completed Phase 2 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy March 28, 2019 November 26, 2023
NCT00525525 Completed Phase 2 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma September 2007 May 2013
NCT00526617 Completed Phase 1 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients August 2007
NCT00527657 Completed Phase 1 Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients February 9, 2006 February 2, 2012
NCT00544284 Completed Phase 1 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment January 2005 January 2012
NCT00544817 Completed Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme April 2007 August 2010
NCT00547131 Completed Phase 1 Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors January 2006 May 2009
NCT03776071 Completed Phase 3 A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 December 16, 2020 February 29, 2024
NCT00553150 Completed Phase 1/Phase 2 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma March 2009 November 15, 2019
NCT00568048 Completed Phase 2 Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery December 2007 October 2011
NCT00575887 Completed Phase 2 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma August 2006 March 2009
NCT00576680 Completed Phase 1/Phase 2 RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors May 2008 March 29, 2019
NCT00582075 Completed Phase 2 Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases July 2002 June 2015
NCT00588341 Completed Phase 2 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection September 2005 March 2009
NCT00589875 Completed Phase 2 Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma March 2007 August 2016
NCT00597402 Completed Phase 2 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas July 2007 May 2013
NCT00602576 Completed Phase 2 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma January 1, 2005 July 26, 2009
NCT00611247 Completed Phase 2 Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia December 2007 January 2010
NCT00617539 Completed Phase 2 Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases February 2005 January 2014
NCT00619112 Completed Phase 2 Temozolomide in Treating Patients With Recurrent High-Grade Glioma October 2007 September 2012
NCT00626015 Completed Phase 1 Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery March 2007 February 2013
NCT00626405 Completed Phase 2 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery August 2008 November 2012
NCT00639262 Completed Phase 1 Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors March 2008 September 2012
NCT00643097 Completed Phase 2 Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme September 2007 November 2016
NCT00650923 Completed Phase 1 Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma July 2008 December 2013
NCT00657267 Completed Phase 2 Dose-Intense Temozolomide in Recurrent Glioblastoma May 2008 October 2013
NCT00662506 Completed Phase 1/Phase 2 Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma April 2008 April 2014
NCT00684567 Completed Phase 2 Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) September 27, 2005 October 31, 2007
NCT00686725 Completed Phase 4 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) June 24, 2008 September 28, 2011
NCT00687323 Completed Phase 2 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) July 30, 2007 December 23, 2012
NCT00689221 Completed Phase 3 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status September 2008 August 2013
NCT00704080 Completed Phase 1 A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas August 2008 February 2013
NCT00704808 Completed Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) May 2006 December 2008
NCT00714181 Completed Phase 1 Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors June 2008 June 2013
NCT00715793 Completed Phase 1/Phase 2 Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma June 2008 August 2015
NCT00717210 Completed Phase 3 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide June 1999 March 2008
NCT00720564 Completed Phase 1 Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma April 2008 February 2009
NCT00723827 Completed Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) March 2008 September 2011
NCT00725010 Completed Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816) April 2007 April 2009
NCT00731731 Completed Phase 1/Phase 2 Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme July 10, 2009 November 1, 2019
NCT03477110 Completed Early Phase 1 Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma May 4, 2018 January 26, 2024
NCT00740636 Completed Phase 2 Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer August 2008 February 2013
NCT00749723 Completed Phase 2/Phase 3 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children February 1, 2006 January 31, 2016
NCT03426891 Completed Phase 1 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma March 16, 2018 June 28, 2023
NCT03425292 Completed Phase 1 A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer March 1, 2018 October 27, 2023
NCT03388372 Completed Phase 2 Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma August 18, 2010 March 23, 2017
NCT00770471 Completed Phase 1 ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme July 13, 2009 March 1, 2012
NCT00783393 Completed Phase 2 SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) May 27, 2003 June 17, 2005
NCT00786669 Completed Phase 1 A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors October 2008 November 2012
NCT00792012 Completed Phase 1 A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma November 2005 July 2016
NCT00804908 Completed Phase 2 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma February 2009 January 2016
NCT00805961 Completed Phase 2 RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM January 2009 May 2013
NCT03345095 Completed Phase 3 A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma July 26, 2018 June 30, 2023
NCT00813943 Completed Phase 2 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status March 2009 August 2013
NCT00820963 Completed Phase 3 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme July 2006
NCT00826241 Completed Phase 2 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma January 2009 July 31, 2018
NCT00831545 Completed Phase 2 Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) December 1, 2000 October 20, 2006
NCT00841555 Completed Phase 1 Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma February 13, 2009 November 25, 2014
NCT00869050 Completed Phase 2 Capecitabine and Temozolomide for Neuroendocrine Cancers August 2005 October 2014
NCT00869401 Completed Phase 1/Phase 2 Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme June 2009 November 15, 2019
NCT00876993 Completed Phase 1 Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors September 2008 September 2015
NCT00884741 Completed Phase 3 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma April 15, 2009 March 17, 2013
NCT00890786 Completed Early Phase 1 A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas May 2009 December 2017
NCT00892385 Completed Phase 1 Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors August 16, 2007 March 8, 2017
NCT03310372 Completed Phase 2 Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme February 13, 2008 June 26, 2012
NCT00905060 Completed Phase 2 HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM June 29, 2009 June 3, 2014
NCT03291990 Completed Early Phase 1 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme October 18, 2017 August 19, 2020
NCT00916409 Completed Phase 3 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) June 2009 March 2017
NCT03257618 Completed N/A Quality of Life and Neurocognitive Functioning July 27, 2017 December 31, 2021
NCT00943826 Completed Phase 3 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma June 29, 2009 September 9, 2015
NCT00946335 Completed Phase 1 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors July 2009 June 2014
NCT03232424 Completed Phase 1 NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma July 26, 2017 December 7, 2022
NCT00960492 Completed Phase 1 Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma September 2009 October 2013
NCT03224104 Completed Phase 1 Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma June 12, 2018 May 5, 2022
NCT00967330 Completed Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma June 2010 September 2014
NCT00970996 Completed Phase 1 Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma September 2009 December 2012
NCT00977431 Completed Phase 1 Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform September 17, 2009 September 12, 2017
NCT00979017 Completed Phase 2 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme November 2009 January 2013
NCT00990652 Completed Phase 2 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide May 2009 October 2012
NCT00993044 Completed Phase 1 A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin September 2009 February 2013
NCT00994071 Completed Phase 1 A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors September 22, 2009 March 19, 2013
NCT01004874 Completed Phase 2 Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma December 30, 2009 November 2, 2021
NCT01005472 Completed Phase 1 Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma December 1, 2008 January 17, 2018
NCT01013285 Completed Phase 2 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma June 2006 August 2015
NCT01015534 Completed Phase 2 Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment January 2006 October 2009
NCT01019434 Completed Phase 2 Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma October 2009 March 2014
NCT01043536 Completed Phase 1 Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults September 2009
NCT01048554 Completed Phase 2 Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System November 2009 September 2011
NCT01051596 Completed Phase 2 A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer September 2009 December 2013
NCT01055314 Completed Phase 2 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma January 2010 June 2016
NCT01062425 Completed Phase 2 Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma February 26, 2010 May 20, 2022
NCT01076530 Completed Phase 1 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors February 2010
NCT01085422 Completed Phase 1 A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer April 2010 June 2011
NCT01102595 Completed Phase 2 Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma December 2009 December 2014
NCT01113957 Completed Phase 2 A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer March 2010 June 2013
NCT01115491 Completed Phase 2 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme June 2010 July 2012
NCT01119508 Completed Phase 2 Ipilimumab + Temozolomide in Metastatic Melanoma May 2010 August 2016
NCT01119599 Completed Phase 1 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma May 2010
NCT01120639 Completed Phase 1/Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform April 2010 November 15, 2020
NCT01124734 Completed Phase 2 High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma May 2010 July 1, 2018
NCT01127594 Completed Phase 1 Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion July 2010 June 2014
NCT01141244 Completed Phase 1 Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors June 2010
NCT01143402 Completed Phase 2 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye June 2010 May 2016
NCT01149109 Completed Phase 3 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients October 2010 April 6, 2017
NCT01149850 Completed Phase 2 Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma April 28, 2010 December 8, 2023
NCT01164189 Completed Phase 2 Bevacizumab in Recurrent Grade II and III Glioma February 2011 September 24, 2017
NCT03150810 Completed Phase 1/Phase 2 Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors June 28, 2017 May 4, 2023
NCT03139916 Completed Phase 2 Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma September 13, 2017 August 31, 2022
NCT01193140 Completed Phase 2 To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors July 2010 November 2011
NCT01196416 Completed Phase 1/Phase 2 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma August 2010 August 2015
NCT03139331 Completed Phase 1 PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma June 6, 2017 September 30, 2020
NCT01209442 Completed Phase 2 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme September 16, 2010 February 3, 2017
NCT02330991 Completed Phase 2 A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse January 2015 September 2020
NCT02364206 Completed Phase 1/Phase 2 Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma June 8, 2015 August 2019
NCT02343081 Completed Phase 4 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System January 2012 October 2013
NCT02343406 Completed Phase 2 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas February 17, 2015 June 24, 2019
NCT02358356 Completed Phase 2 Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study November 2015 October 31, 2021
NCT00003466 Completed Phase 2 Temozolomide in Treating Patients With Progressive Low-Grade Glioma March 1998 July 2005
NCT00003708 Completed Phase 1 Chemotherapy in Treating Patients With Advanced Solid Tumors July 1998 May 2000
NCT00003731 Completed Phase 2 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors December 1998
NCT00004068 Completed Phase 2 Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor March 1999 April 2003
NCT00004113 Completed Phase 2 Temozolomide in Treating Patients With Recurrent Malignant Glioma June 1999 October 2001
NCT00004200 Completed Phase 2 Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme October 1999
NCT00005037 Completed Phase 2 Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer January 2000 April 2008
NCT00005597 Completed Phase 2 S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors April 2000 October 2005
NCT00005637 Completed Phase 1 Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma December 1999 December 2009
NCT00005815 Completed Phase 1/Phase 2 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma December 1999 August 2004
NCT00005951 Completed Phase 1 Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma August 2000 April 2006
NCT00005952 Completed Phase 1/Phase 2 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors August 2000 November 2005
NCT00005954 Completed Phase 2 Temozolomide in Treating Patients With Brain Metastases August 2000 June 2003
NCT00005955 Completed Phase 2 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors August 2000 September 2002
NCT00006024 Completed Phase 1 Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma November 2000 September 2006
NCT00006025 Completed Phase 1 Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma January 5, 2001 December 1, 2007
NCT00006043 Completed Phase 2 Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin February 2000 November 2001
NCT00006353 Completed Phase 3 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme July 2000
NCT00006358 Completed Phase 2 Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor June 13, 2000 July 20, 2006
NCT00006474 Completed Phase 1 Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma March 2001 August 2004
NCT00006877 Completed Phase 2 Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer July 2000 September 2003
NCT00012116 Completed Phase 2 Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain October 2000 April 2002
NCT00014092 Completed Phase 2 Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery December 1999 December 2003
NCT00014261 Completed Phase 1 Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors October 2000 November 2002
NCT00020150 Completed Phase 1 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors June 2000
NCT00022711 Completed Phase 2 Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer January 2002 January 2004
NCT00025558 Completed Phase 1 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer October 2000
NCT00026494 Completed Phase 1/Phase 2 Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases July 2001 April 2008
NCT00027625 Completed Phase 1 Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma January 28, 2002 November 1, 2005
NCT00027742 Completed Phase 2 Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma May 2001 June 2005
NCT00028795 Completed Phase 2 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma December 2002 March 2012
NCT00033280 Completed Phase 2 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas July 2002 May 14, 2018
NCT00039494 Completed Phase 2 Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors December 2002
NCT00047294 Completed Phase 2 Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme April 2001 September 2007
NCT00049361 Completed Phase 2 Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases January 1, 2004 December 7, 2004
NCT00049387 Completed Phase 1 Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma September 2002 June 2007
NCT00050986 Completed Phase 1/Phase 2 Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme December 2002 October 2008
NCT00052455 Completed Phase 3 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma October 2002 September 2010
NCT00052780 Completed Phase 1 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors October 2002
NCT00068952 Completed Phase 3 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme August 2003 March 2006
NCT00072163 Completed Phase 2 Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma October 2003
NCT00072345 Completed Phase 2 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma July 2003
NCT00076856 Completed Phase 2 Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) March 31, 2004 March 31, 2006
NCT00077207 Completed N/A Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma July 2004 December 2013
NCT00077454 Completed Phase 1 Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors February 2004
NCT00080938 Completed Phase 2 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer December 20, 2005 February 2009
NCT00083070 Completed Phase 1 Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia March 2004 June 2008
NCT00084838 Completed Phase 2 Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT February 2003 March 2013
NCT00085254 Completed Phase 1/Phase 2 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme April 2005 November 2012
NCT00086879 Completed Phase 2 Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme May 2004 March 2011
NCT00091572 Completed Phase 3 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) October 20, 2004 December 31, 2007
NCT00093353 Completed Phase 1 N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma May 2004
NCT00098436 Completed Phase 1 Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias September 2004 August 2008
NCT00098774 Completed Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma October 2004 September 2014
NCT00098865 Completed Phase 2 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma September 2002 June 2010
NCT00099125 Completed Phase 2 Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme November 2004 November 2013
NCT00100802 Completed Phase 2 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas March 21, 2005 June 30, 2017
NCT00104988 Completed Phase 2 S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery June 2005 August 2009
NCT00112502 Completed Phase 2 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme September 2005 September 2014
NCT02511132 Completed Phase 2 A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma February 10, 2016 December 23, 2020
NCT02502708 Completed Phase 1 Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors October 2015 February 28, 2020
NCT02029573 Completed Phase 2 Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma January 1, 2014 December 31, 2016
NCT02044120 Completed Phase 1 ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma May 2014 January 2021
NCT02049593 Completed Phase 1 PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors June 12, 2014 October 7, 2019
NCT02052648 Completed Phase 1/Phase 2 Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors March 2014 June 20, 2019
NCT02414009 Completed Phase 2 Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients September 2014 July 30, 2019
NCT02392793 Completed Phase 1 Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies March 25, 2015 August 30, 2019
NCT02092038 Completed Phase 1 Preoperative Chemoradiation for Glioblastoma November 2014 July 2015
NCT02116777 Completed Phase 1/Phase 2 Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies May 16, 2014 December 31, 2018
NCT02389738 Completed Early Phase 1 Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration February 2015 February 1, 2018
NCT00003464 Completed Phase 2 Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme September 1997 August 2003
NCT02193347 Completed Phase 1 IDH1 Peptide Vaccine for Recurrent Grade II Glioma January 28, 2016 February 3, 2020
NCT02378532 Completed Phase 1 The Addition of Chloroquine to Chemoradiation for Glioblastoma August 2016 July 30, 2019
NCT02209948 Completed Phase 2 Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. August 22, 2014 June 14, 2019
NCT02227901 Completed Phase 1 Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme September 2002 April 2014
NCT02263105 Completed Phase 2 Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas October 2014 June 2018
NCT00003465 Completed Phase 2 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma March 1998 February 2001
NCT02311920 Completed Phase 1 Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma April 16, 2015 December 22, 2022
NCT02315534 Completed Phase 1/Phase 2 A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma March 2015 June 24, 2019
NCT02366728 Completed Phase 2 DC Migration Study for Newly-Diagnosed GBM October 12, 2015 October 31, 2020
NCT02337426 Completed Phase 1 Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme February 13, 2015 November 9, 2017
NCT01217437 Completed Phase 2 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors November 22, 2010 June 30, 2021
NCT01220271 Completed Phase 1/Phase 2 A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma April 2011 November 2016
NCT01222221 Completed Phase 1 Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme July 2010 February 2015
NCT03018288 Completed Phase 2 Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) September 21, 2017 December 20, 2022
NCT01236560 Completed Phase 2/Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma January 26, 2011 December 31, 2023
NCT01242566 Completed Phase 2 Temozolomide in Elderly Patients With KPS < 70 July 2007 September 2010
NCT01269424 Completed Phase 1 BG & TMZ Therapy of Glioblastoma Multiforme November 22, 2011 September 26, 2022
NCT02898012 Completed Phase 2 Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status October 2010 June 2013
NCT01294735 Completed Phase 1 Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) February 2011 May 2012
NCT02843230 Completed Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI August 1, 2016 January 31, 2022
NCT01328535 Completed Phase 2 Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery January 2011 July 11, 2018
NCT01342757 Completed N/A Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma December 2010 May 2012
NCT01345370 Completed Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients March 2009 June 2015
NCT01390571 Completed Phase 1 Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma July 2011 June 20, 2017
NCT01402063 Completed Phase 2 PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation September 2011 June 2015
NCT02805179 Completed Phase 2 A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma September 22, 2016 November 18, 2020
NCT01465659 Completed Phase 1/Phase 2 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery December 12, 2011 January 27, 2021
NCT01466686 Completed Phase 2 Low Dose Radiation Therapy for Glioblastoma Multiforme September 2012 December 2022
NCT01467986 Completed Phase 2 Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma August 2013 September 30, 2020
NCT02799238 Completed Phase 2 Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma March 2016 February 24, 2020
NCT01480050 Completed Phase 1 Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma May 31, 2012 June 1, 2017
NCT01480479 Completed Phase 3 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma November 2011 November 2016
NCT01502241 Completed Phase 3 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly January 2005 November 2011
NCT01506609 Completed Phase 2 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer January 23, 2012 September 2, 2020
NCT01514201 Completed Phase 1/Phase 2 Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas February 1, 2012 March 28, 2018
NCT02770378 Completed Phase 1/Phase 2 A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma November 2016 December 2020
NCT01525082 Completed Phase 2 Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors December 2012 December 31, 2019
NCT01528046 Completed Phase 1 Metformin in Children With Relapsed or Refractory Solid Tumors September 24, 2012 February 3, 2020
NCT01550224 Completed Phase 2 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) May 1, 2013 November 17, 2014
NCT01601535 Completed Phase 1/Phase 2 Study of MLN8237 in Combination With Irinotecan and Temozolomide May 2012 July 25, 2018
NCT01638546 Completed Phase 2 Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer June 2012 January 2017
NCT00003176 Completed Phase 2 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma March 25, 1998 January 6, 2004
NCT02667587 Completed Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) May 9, 2016 April 9, 2024
NCT01704287 Completed Phase 2 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) November 20, 2012 January 31, 2019
NCT02661282 Completed Phase 1/Phase 2 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma June 1, 2016 February 23, 2022
NCT01740258 Completed Phase 2 Bevacizumab Beyond Progression (BBP) January 2013 November 14, 2019
NCT02654106 Completed Phase 2 Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases October 2011 November 2015
NCT01767194 Completed Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma February 12, 2013 September 30, 2022
NCT02617589 Completed Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) March 1, 2016 March 4, 2022
NCT01781403 Completed Phase 1 Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer May 10, 2013 May 4, 2016
NCT01790503 Completed Phase 1/Phase 2 A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma July 18, 2013 March 4, 2020
NCT01800695 Completed Phase 1 Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme April 2, 2013 June 19, 2017
NCT01827384 Completed Phase 2 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations January 7, 2014 October 8, 2021
NCT02596828 Completed Phase 2 Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma April 2016 April 2021
NCT01835145 Completed Phase 2 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery July 31, 2013 November 1, 2019
NCT01847235 Completed Phase 2 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial May 2013 March 2016
NCT01860638 Completed Phase 2 A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma August 19, 2013 May 5, 2017
NCT02590263 Completed Phase 1/Phase 2 Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma August 24, 2015 August 27, 2020
NCT01891747 Completed Phase 1 A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma July 2013 January 31, 2022
NCT02573324 Completed Phase 3 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification January 4, 2015 April 4, 2022
NCT01907165 Completed Early Phase 1 Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide October 10, 2013 February 9, 2018
NCT01957956 Completed Early Phase 1 Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma November 11, 2013 November 16, 2016
NCT01977677 Completed Phase 1/Phase 2 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma November 2014 September 2018
NCT00003304 Completed Phase 2 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors April 1998
NCT04164199 Enrolling by invitation Phase 3 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies December 19, 2019 December 2026
NCT04945148 Not yet recruiting Phase 2 Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide May 2023 October 2026
NCT06186440 Not yet recruiting Phase 1/Phase 2 Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma January 1, 2024 January 1, 2025
NCT05096481 Not yet recruiting Phase 2 PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma June 15, 2024 June 15, 2030
NCT06202066 Not yet recruiting Phase 2 Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors July 15, 2024 January 15, 2028
NCT04199026 Not yet recruiting Early Phase 1 Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma January 31, 2025 December 31, 2025
NCT06448286 Not yet recruiting Phase 3 PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma June 1, 2024 June 1, 2027
NCT04157478 Not yet recruiting Phase 2 Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma January 2020 December 2024
NCT06218524 Not yet recruiting Phase 2 The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM December 1, 2024 July 31, 2028
NCT06413706 Not yet recruiting Phase 2 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy June 2024 February 2028
NCT06410248 Not yet recruiting Phase 1 Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma July 12, 2024 May 12, 2030
NCT06419946 Not yet recruiting Phase 3 Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma May 15, 2024 December 15, 2031
NCT05128734 Not yet recruiting Phase 2 Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) July 1, 2024 July 1, 2028
NCT04373785 Not yet recruiting Phase 1/Phase 2 NG101m Adjuvant Therapy in Glioblastoma Patients January 1, 2024 December 31, 2027
NCT04890093 Not yet recruiting Phase 1/Phase 2 Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors June 23, 2024 December 31, 2026
NCT02496988 Not yet recruiting Phase 4 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas July 2015 July 2030
NCT06388733 Not yet recruiting Phase 3 A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma June 2024 March 2028
NCT02494804 Not yet recruiting Phase 1/Phase 2 Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas July 2015 July 2030
NCT06450041 Not yet recruiting Phase 2 NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial July 2024 December 2038
NCT06428045 Not yet recruiting Phase 1 STARLITE for Unresectable High-Grade Gliomas August 31, 2024 May 31, 2029
NCT03554707 Not yet recruiting Early Phase 1 SGT-53 in Children With Recurrent or Progressive CNS Malignancies June 2022 December 2024
NCT05439278 Not yet recruiting Phase 3 Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma August 1, 2022 July 31, 2027
NCT04587830 Recruiting Phase 1 ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme September 14, 2020 May 30, 2027
NCT01649830 Recruiting Phase 3 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma July 2012 August 2026
NCT01837862 Recruiting Phase 1/Phase 2 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas October 22, 2013 April 2025
NCT01985087 Recruiting Phase 1/Phase 2 A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 September 2014 May 2025
NCT02177578 Recruiting Phase 2 Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme July 8, 2014 December 2032
NCT02287428 Recruiting Phase 1 Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM November 2014 June 2026
NCT02685605 Recruiting Phase 3 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme December 9, 2016 June 2026
NCT02813135 Recruiting Phase 1/Phase 2 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors August 3, 2016 August 2027
NCT02970448 Recruiting Early Phase 1 Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas August 24, 2017 June 1, 2024
NCT02977780 Recruiting Phase 2 INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) February 9, 2017 December 31, 2025
NCT03008148 Recruiting Phase 2/Phase 3 Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM October 11, 2018 April 2025
NCT03011671 Recruiting Phase 1 Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma October 3, 2018 October 2026
NCT03122197 Recruiting Early Phase 1 Study of Letrozole in Recurrent Gliomas May 16, 2017 December 2024
NCT03213002 Recruiting Phase 1/Phase 2 Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM June 13, 2017 June 2026
NCT03359005 Recruiting Phase 2 Irinotecan and Temozolomide for Ewing Sarcoma February 7, 2018 February 28, 2025
NCT03495960 Recruiting Phase 2 Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System June 15, 2019 December 31, 2024
NCT03554473 Recruiting Phase 1/Phase 2 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers September 11, 2018 January 15, 2025
NCT03650257 Recruiting Phase 2 A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 August 21, 2019 August 20, 2024
NCT03672773 Recruiting Phase 2 Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer October 31, 2018 October 1, 2025
NCT03687957 Recruiting Phase 1/Phase 2 rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide January 4, 2019 January 31, 2032
NCT03715933 Recruiting Phase 1 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas October 10, 2018 July 2026
NCT03746080 Recruiting Phase 2 Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma December 4, 2018 July 2027
NCT03749187 Recruiting Phase 1 BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas April 3, 2019 July 30, 2029
NCT03830918 Recruiting Phase 1/Phase 2 Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy March 6, 2019 January 3, 2026
NCT03899155 Recruiting Phase 2 Pan Tumor Rollover Study August 9, 2019 August 25, 2029
NCT03970447 Recruiting Phase 2/Phase 3 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma July 30, 2019 June 2028
NCT04049669 Recruiting Phase 2 Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG October 2, 2019 October 2, 2027
NCT04077866 Recruiting Phase 1/Phase 2 B7-H3 CAR-T for Recurrent or Refractory Glioblastoma June 1, 2023 August 1, 2025
NCT04211675 Recruiting Phase 1/Phase 2 NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab September 1, 2022 December 2025
NCT04239092 Recruiting Phase 1 9-ING-41 in Pediatric Patients With Refractory Malignancies. June 5, 2020 December 2024
NCT04316039 Recruiting Phase 2/Phase 3 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery April 10, 2018 December 31, 2028
NCT04337177 Recruiting Phase 1 Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors October 25, 2021 June 2024
NCT04385173 Recruiting Phase 1 Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma December 1, 2022 May 1, 2024
NCT04394858 Recruiting Phase 2 Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer March 17, 2021 February 28, 2025
NCT04443010 Recruiting Phase 1/Phase 2 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma January 20, 2021 December 2026
NCT04462965 Recruiting Phase 2 Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study May 30, 2020 June 30, 2025
NCT04474353 Recruiting Phase 1 Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma May 21, 2021 November 2024
NCT04477200 Recruiting Phase 1 Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma August 5, 2020 October 2027
NCT04478279 Recruiting Phase 1/Phase 2 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors July 1, 2020 December 2025
NCT04523688 Recruiting Phase 2 Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma March 25, 2021 December 2025
NCT04555577 Recruiting Phase 1 Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma September 20, 2020 October 30, 2025
NCT04566380 Recruiting Phase 2 ONO-4538 Phase II Rollover Study (ONO-4538-98) September 10, 2020 December 31, 2026
NCT04574856 Recruiting Phase 2 Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma November 4, 2020 July 2024
NCT04614909 Recruiting Early Phase 1 Study of Pamiparib in Newly Diagnosed and rGBM January 11, 2021 December 2024
NCT04623931 Recruiting Phase 2 Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas January 30, 2020 December 31, 2026
NCT04625907 Recruiting Phase 1/Phase 2 FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma September 17, 2020 June 2030
NCT04737889 Recruiting Phase 2 Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma January 13, 2021 January 13, 2026
NCT04796012 Recruiting Phase 1/Phase 2 VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors April 18, 2023 January 2025
NCT04881032 Recruiting Phase 1/Phase 2 AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma March 7, 2022 March 2027
NCT04910022 Recruiting Phase 1/Phase 2 Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma December 1, 2021 November 30, 2025
NCT04919382 Recruiting Phase 2 Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer January 26, 2022 December 31, 2025
NCT04984733 Recruiting Phase 2 Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer September 28, 2021 July 2026
NCT05030298 Recruiting Phase 1/Phase 2 Preoperative Radiosurgery for the Treatment of High Grade Glioma, The NeoGlioma Study May 23, 2023 September 15, 2025
NCT05031975 Recruiting Phase 2 Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy May 2, 2022 June 1, 2024
NCT05040360 Recruiting Phase 2 Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors May 5, 2022 March 31, 2025
NCT05052957 Recruiting Phase 2 hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) January 20, 2023 December 1, 2024
NCT05083754 Recruiting Phase 1 Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma August 31, 2022 January 2027
NCT05095376 Recruiting Phase 3 Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma November 29, 2021 August 8, 2031
NCT05106023 Recruiting Phase 2 To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma January 21, 2022 December 31, 2023
NCT05109728 Recruiting Phase 1 A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. May 10, 2022 July 28, 2026
NCT05136326 Recruiting Phase 2 Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer December 1, 2021 December 2026
NCT05142241 Recruiting Phase 2 Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial July 11, 2022 April 15, 2026
NCT05236036 Recruiting Phase 1 Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma August 8, 2022 January 3, 2027
NCT05247905 Recruiting Phase 2 Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors March 16, 2022 October 2033
NCT05384821 Recruiting Phase 1/Phase 2 Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) September 14, 2022 October 2028
NCT05417594 Recruiting Phase 1/Phase 2 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies June 24, 2022 January 12, 2026
NCT05429502 Recruiting Phase 1/Phase 2 Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors December 27, 2022 January 29, 2029
NCT05440786 Recruiting Phase 2 CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma September 20, 2022 September 10, 2028
NCT05463848 Recruiting Phase 2 Surgical Pembro +/- Olaparib w TMZ for rGBM October 21, 2022 December 1, 2025
NCT05588453 Recruiting Phase 1/Phase 2 Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain January 1, 2023 December 31, 2025
NCT05600491 Recruiting Phase 3 A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme November 8, 2015 December 1, 2025
NCT05629702 Recruiting Phase 2 ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids February 3, 2023 February 2027
NCT05634707 Recruiting Early Phase 1 Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT) August 5, 2023 June 2026
NCT05664464 Recruiting Phase 1/Phase 2 Glutamate Inhibitors in Glioblastoma January 1, 2023 December 2026
NCT05685004 Recruiting Phase 2/Phase 3 Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) September 15, 2023 March 2026
NCT05691491 Recruiting Phase 1/Phase 2 Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness September 28, 2023 January 31, 2025
NCT05698524 Recruiting Phase 1 A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma June 26, 2023 June 2027
NCT05728619 Recruiting Phase 1/Phase 2 HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer February 3, 2023 October 2024
NCT05739942 Recruiting Phase 1 Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma May 15, 2024 June 1, 2026
NCT05765812 Recruiting Phase 1/Phase 2 A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma May 15, 2023 September 2028
NCT05769660 Recruiting Phase 1 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Temozolomide in Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM) November 29, 2022 October 31, 2024
NCT05781321 Recruiting Phase 2 Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study March 23, 2023 March 2, 2028
NCT05879367 Recruiting Phase 1 Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma July 24, 2023 December 15, 2024
NCT05885386 Recruiting Phase 2 A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL April 1, 2023 October 1, 2025
NCT05896007 Recruiting Phase 2 Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT July 13, 2023 December 31, 2025
NCT05902169 Recruiting Phase 3 Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM January 29, 2024 June 30, 2028
NCT05999994 Recruiting Phase 2 A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer January 22, 2020 May 1, 2026
NCT06006273 Recruiting Phase 1/Phase 2 A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors August 16, 2023 December 31, 2028
NCT06012695 Recruiting Phase 1/Phase 2 NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma August 11, 2023 September 30, 2029
NCT06013618 Recruiting Phase 2 Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma June 19, 2023 December 31, 2024
NCT06023641 Recruiting Phase 1/Phase 2 Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease March 13, 2024 October 2037
NCT06095375 Recruiting Phase 1 Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients July 4, 2022 December 2025
NCT06172296 Recruiting Phase 3 Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma April 19, 2024 December 31, 2029
NCT06283927 Recruiting The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) January 1, 2023 January 1, 2028
NCT06346067 Recruiting Phase 3 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) April 29, 2024 December 2028
NCT05432804 Suspended Phase 1/Phase 2 Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment March 20, 2023 June 30, 2026
NCT03197506 Suspended Phase 2 Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma September 15, 2017 August 31, 2024
NCT05432791 Suspended Phase 2/Phase 3 Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working March 30, 2023 March 9, 2030
NCT02329795 Terminated Image-derived Prediction of Response to Chemo-radiation in Glioblastoma October 2014 October 2016
NCT00516282 Terminated Phase 1 VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma August 2007 October 2009
NCT00915694 Terminated Phase 1 Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme April 2009 December 2015
NCT02168270 Terminated Phase 1 Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma June 16, 2014 August 20, 2015
NCT02085304 Terminated Phase 1/Phase 2 Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM May 7, 2013 May 29, 2018
NCT02394665 Terminated Phase 2 Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma March 2015 September 2016
NCT02395692 Terminated Phase 2 Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma December 18, 2015 February 16, 2017
NCT01105702 Terminated Phase 2 Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma May 2010 April 2015
NCT02414165 Terminated Phase 2/Phase 3 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma November 30, 2015 December 20, 2019
NCT00629187 Terminated Phase 1 Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy April 2004 April 2012
NCT00515788 Terminated Phase 1 DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis February 2006 June 2009
NCT02046187 Terminated Phase 1/Phase 2 Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma October 2013 February 2017
NCT02477813 Terminated Phase 2 Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation January 2015 June 2018
NCT02025881 Terminated Phase 1/Phase 2 Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma September 14, 2013 October 25, 2020
NCT02023905 Terminated Phase 2 Everolimus With and Without Temozolomide in Adult Low Grade Glioma March 19, 2014 September 30, 2021
NCT03419403 Terminated Phase 3 UNITE Study: Understanding New Interventions With GBM ThErapy July 30, 2018 March 3, 2020
NCT02507232 Terminated Early Phase 1 Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas April 17, 2017 July 27, 2020
NCT02510950 Terminated Phase 1 Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma December 3, 2015 February 14, 2017
NCT04851834 Terminated Phase 1/Phase 2 NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma August 25, 2021 November 8, 2022
NCT02530502 Terminated Phase 1 Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma September 30, 2015 February 12, 2020
NCT00512798 Terminated Phase 1/Phase 2 Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma June 2003 March 2008
NCT01868906 Terminated Phase 2 FMISO-PET in Brain Tumors and SCS Effect June 2013 September 17, 2017
NCT01857752 Terminated Phase 2 Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala March 2012 June 2015
NCT01110876 Terminated Phase 1/Phase 2 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) June 2011 July 2014
NCT03168919 Terminated N/A Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma October 6, 2016 June 12, 2018
NCT03927222 Terminated Phase 2 Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma September 30, 2019 February 10, 2023
NCT03930771 Terminated Phase 2 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas May 21, 2019 October 1, 2021
NCT00724841 Terminated Phase 1/Phase 2 A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma June 2008 August 2010
NCT01182350 Terminated Phase 2 Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) September 2011 June 2016
NCT00005812 Terminated Phase 2 Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma January 2000 May 2004
NCT00505635 Terminated Phase 2 Biochemotherapy With Temozolomide for Metastatic Melanoma March 2007 April 2010
NCT01700569 Terminated Phase 1 Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma January 2013 April 16, 2021
NCT03495921 Terminated Phase 3 A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide August 21, 2018 January 20, 2022
NCT03246113 Terminated Phase 1 Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma March 19, 2018 May 9, 2019
NCT00756106 Terminated N/A MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma July 2008 February 2012
NCT01205828 Terminated Phase 2 ABT-888 and Temozolomide for Liver Cancer August 2010 October 2014
NCT01601184 Terminated Phase 1/Phase 2 Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway June 2012 October 2017
NCT01590082 Terminated Phase 1/Phase 2 Doxycycline, Temozolomide and Ipilimumab in Melanoma November 2012 July 2015
NCT00960063 Terminated Phase 1 A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) November 11, 2009 December 22, 2010
NCT01517776 Terminated Phase 2 Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents January 2012 April 2014
NCT00471653 Terminated Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy November 11, 2006 August 18, 2009
NCT01505608 Terminated Phase 1/Phase 2 Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma December 2011 December 2014
NCT01478321 Terminated Phase 2 Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas December 14, 2011 September 12, 2018
NCT01409174 Terminated Phase 1 IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma February 2013 May 2016
NCT00717275 Terminated Phase 2 Study of Temozolomide to Treat Newly Diagnosed Brain Metastases September 2008 June 2011
NCT00248534 Terminated Phase 2 Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma September 2005 September 2012
NCT03119064 Terminated Phase 1/Phase 2 BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma November 30, 2017 October 8, 2021
NCT01313884 Terminated Phase 2 Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma May 2011 July 2014
NCT01284335 Terminated Phase 1 A Safety Study in Participants With Advanced Solid Tumors July 2008 May 2016
NCT00437957 Terminated Phase 1 Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases December 2006 April 2009
NCT00436436 Terminated Phase 2 O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy November 13, 2006 April 14, 2010
NCT02943733 Terminated Phase 1 Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs August 22, 2017 January 31, 2022
NCT00068666 Terminated Phase 2 Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System January 2004 March 2010
NCT00423150 Terminated Phase 2 Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) January 26, 2007 June 11, 2009
NCT01235793 Terminated Phase 2 The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma October 14, 2010 April 18, 2018
NCT00669669 Terminated Phase 1/Phase 2 O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas February 25, 2009 January 20, 2021
NCT00096265 Terminated Phase 3 Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer October 6, 2004 April 1, 2012
NCT03363659 Terminated Phase 2 Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme March 28, 2018 January 13, 2022
NCT00961844 Terminated Phase 1/Phase 2 Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma August 2009 June 2012
NCT00003567 Terminated Phase 1 Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma May 1999 February 2007
NCT03705351 Terminated Phase 1 Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM December 2, 2019 February 24, 2022
NCT00034697 Terminated Phase 2 Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) June 28, 2001 January 30, 2003
NCT00376103 Terminated Phase 1/Phase 2 Radiation Boost for Newly Diagnosed Glioblastoma Multiforme August 2006
NCT00238277 Terminated Phase 2 Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme February 15, 2005 December 11, 2007
NCT00365222 Terminated Phase 2 Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma July 2006 June 2007
NCT00568451 Terminated Phase 2 Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma June 2006 April 2012
NCT00020839 Terminated Phase 3 Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain April 2001
NCT00811993 Terminated Phase 1 A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors February 2009 December 2012
NCT00897377 Terminated Phase 3 Treatment Strategy for Low-grade Gliomas December 2007
NCT03763422 Terminated Phase 3 Trial in Low Grade Glioma Patients: Wait or Treat March 16, 2020 December 29, 2021
NCT00548938 Terminated Phase 2 Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM October 2007 October 2010
NCT00761280 Terminated Phase 3 Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma December 2008 June 2012
NCT01014767 Terminated Phase 3 Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors November 2009 January 2014
NCT00734526 Terminated Phase 1 Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma December 18, 2008 December 2012
NCT00004106 Terminated Phase 2 Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome May 1998 April 2006
NCT00638963 Terminated Phase 2 Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) October 2, 2008 June 30, 2010
NCT00272415 Terminated Phase 1 A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma October 2005
NCT00632203 Terminated Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) March 4, 2008 January 7, 2011
NCT02343549 Terminated Phase 2 A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) January 2015 July 11, 2020
NCT02340156 Terminated Phase 2 Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma December 2014 November 2018
NCT01181193 Unknown status Phase 1/Phase 2 Vitamin D for Treatment of Glioblastoma Multiforme March 2011 March 2014
NCT03463733 Unknown status Phase 1 Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma) March 2, 2018 June 1, 2022
NCT00014105 Unknown status Phase 1/Phase 2 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme December 2000
NCT00660283 Unknown status Phase 2 A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma January 2009 December 2010
NCT00643825 Unknown status Phase 2 Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients January 2008 January 2012
NCT03607643 Unknown status Phase 1/Phase 2 A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies January 15, 2019 December 15, 2020
NCT03633552 Unknown status Phase 3 Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma March 3, 2018 April 3, 2021
NCT04674527 Unknown status Phase 2 Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma June 1, 2021 June 1, 2023
NCT04689347 Unknown status Phase 1 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. January 1, 2021 January 2023
NCT03687034 Unknown status Phase 1 A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma June 1, 2019 December 31, 2020
NCT00033709 Unknown status Phase 2 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma March 2002
NCT03741244 Unknown status Phase 2 TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT May 6, 2019 February 2023
NCT00521482 Unknown status Phase 2 Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma September 2007 January 2009
NCT03778541 Unknown status Phase 3 HFSRT With Concurrent TMZ for Large BMs December 3, 2018 December 3, 2022
NCT03780569 Unknown status N/A TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM April 27, 2017 January 2019
NCT00516607 Unknown status Phase 1 Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas July 2007
NCT04829097 Unknown status Phase 3 Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma November 1, 2020 November 1, 2023
NCT00514397 Unknown status Phase 2 Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma January 2008
NCT03932981 Unknown status Phase 2 First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression July 26, 2019 September 30, 2023
NCT00492687 Unknown status Phase 2 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas December 2006
NCT00102648 Unknown status Phase 1 Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide December 21, 2004 December 1, 2022
NCT00455286 Unknown status Phase 2 a Phase II Study in Primary Central Nervous System Lymphoma November 2006 November 2011
NCT00394628 Unknown status Phase 1/Phase 2 AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme October 2006
NCT00392886 Unknown status Phase 3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors March 2004
NCT04267146 Unknown status Phase 1/Phase 2 Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma July 15, 2019 January 2024
NCT00383851 Unknown status Phase 2 Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma September 2006 September 2008
NCT00083096 Unknown status Phase 1 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas March 2004
NCT04959500 Unknown status Phase 2 Newly Diagnosed Glioblastoma June 10, 2021 October 31, 2023
NCT00360945 Unknown status Phase 2 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma April 2004
NCT04388033 Unknown status Phase 1/Phase 2 Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. December 2020 December 2023
NCT00005054 Unknown status Phase 2 Temozolomide in Treating Women With Advanced Breast Cancer May 1998
NCT00311857 Unknown status Phase 1/Phase 2 Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) February 2006
NCT00283543 Unknown status Phase 2 Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma September 2002 April 2008
NCT00275067 Unknown status Phase 1/Phase 2 Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery May 2005 May 2021
NCT00004204 Unknown status Phase 2 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma February 2000
NCT04514393 Unknown status Phase 2 Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma October 10, 2020 June 1, 2024
NCT00003747 Unknown status Phase 1 Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma October 1998
NCT02209428 Unknown status Phase 2 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas June 2014 May 2019
NCT02385136 Unknown status Phase 1/Phase 2 Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases April 2015 December 2018
NCT02416999 Unknown status N/A Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas May 2015 May 2018
NCT02446704 Unknown status Phase 1/Phase 2 Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy October 13, 2015 December 2023
NCT02015728 Unknown status N/A Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors December 2013 December 2017
NCT01985451 Unknown status Phase 2 Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL） March 2013 March 2015
NCT01900951 Unknown status Phase 2 Temozolomide as Maintenance Therapy in Small Cell Lung Cancer January 2013 June 2016
NCT02605811 Unknown status Phase 2 Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer September 2015 December 2021
NCT01777919 Unknown status Phase 2 Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform January 2017 January 2020
NCT01765088 Unknown status Phase 3 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas September 2012 December 2019
NCT01735747 Unknown status Phase 2 Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma June 2008 November 2013
NCT02663440 Unknown status Phase 2 Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme January 2016
NCT02672241 Unknown status Phase 2 Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children January 2016 August 2019
NCT02681705 Unknown status Phase 2 Radiation Therapy and Combination Chemotherapy for Medulloblastoma January 2010 December 2016
NCT04547621 Unknown status Phase 1/Phase 2 HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM September 1, 2020 January 1, 2024
NCT02766270 Unknown status Early Phase 1 CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas September 26, 2016 December 2018
NCT02772107 Unknown status Phase 2/Phase 3 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer December 2015 January 2018
NCT04552977 Unknown status Phase 2 A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma September 2020 August 2022
NCT02928575 Unknown status Phase 2 Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma August 2012 June 2017
NCT02934204 Unknown status Phase 2 Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma February 2016 February 2019
NCT02972320 Unknown status Phase 2 Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic June 2016 December 2018
NCT00016055 Unknown status Phase 1 Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma November 2000
NCT00003718 Unknown status Phase 2 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma September 1998
NCT04583020 Unknown status Phase 2 Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma November 12, 2020 December 31, 2023
NCT01217398 Unknown status Phase 2 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye October 2009
NCT03422445 Unknown status Phase 2 A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma January 8, 2018 February 2019
NCT03204032 Unknown status Phase 2 A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor October 2016 September 2018
NCT00875355 Unknown status Phase 2 Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer November 2007
NCT00811759 Unknown status Phase 1/Phase 2 Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma June 2007
NCT03387592 Unknown status Phase 2 CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas March 6, 2017 January 2022
NCT00768911 Unknown status Phase 1 CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme October 2008 June 2011
NCT03480867 Withdrawn Phase 1 Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA) March 2017 November 2023
NCT02599090 Withdrawn Phase 2 Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma December 2008 December 2012
NCT01830101 Withdrawn Phase 3 A Phase III Study of Re-Irradiation in Recurrent Glioblastoma February 2014 November 2017
NCT02065466 Withdrawn Phase 1/Phase 2 Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases July 2014 August 2015
NCT00021307 Withdrawn Phase 1/Phase 2 Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme April 2002
NCT00003273 Withdrawn Phase 2 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor November 1997
NCT00601289 Withdrawn Phase 2 Temozolomide in Treating Patients With Invasive Pituitary Tumors December 2009
NCT04603365 Withdrawn Phase 2 Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer October 18, 2021 May 7, 2023
NCT00385398 Withdrawn Phase 2 QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC July 2008 December 2008
NCT04105374 Withdrawn Phase 2/Phase 3 Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma January 31, 2020 November 30, 2030
NCT00109798 Withdrawn N/A Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma March 2005 July 2006
NCT00943462 Withdrawn Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM June 2009 June 2011
NCT02976441 Withdrawn Early Phase 1 Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas January 2017 February 2018
NCT03796507 Withdrawn Early Phase 1 Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation September 1, 2021 December 15, 2021
NCT04796454 Withdrawn Phase 2 Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer May 2022 August 2026
NCT00601614 Withdrawn Phase 1 Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery January 2008
NCT01260103 Withdrawn Phase 3 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma December 2011 December 2018
NCT02836028 Withdrawn Phase 2 A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer October 2016
NCT02831179 Withdrawn Phase 1 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor December 2017 February 2020
NCT00006263 Withdrawn Phase 2 Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma November 1997
NCT02689336 Withdrawn Phase 2 Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors August 6, 2016 May 31, 2020
NCT01736800 Withdrawn Phase 2 Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors March 2007 November 2014